ARALEN
LOE ApproachingNDAORALTABLET
Approved
Oct 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN is an oral tablet approved in 1949 for unknown indications with undisclosed mechanism of action. The product is a legacy small-molecule NDA currently owned by Sanofi with approaching loss of exclusivity.
LOE Approaching
Legacy product nearing exclusivity cliff with moderate competitive pressure (30/100) suggests defensive commercial posture and potential headcount rationalization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring. Working on ARALEN offers limited career advancement; roles focus on portfolio management and LOE transition planning rather than growth initiatives.
Brand Manager (Legacy)Commercial Operations
Worked on ARALEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.